(Press-News.org) DURHAM, N.C. – A large study addressing the effectiveness and safety of aldosterone antagonist therapy for older heart failure patients has found notable differences between the drug's results in clinical trial vs. what occurs in actual practice, according to researchers at Duke Medicine.
Those differences have been noted anecdotally by doctors, and likely contributed to the slow adoption of aldosterone antagonists in clinical practice, but they had not been confirmed in a large study examining the drugs in real-world situations.
The Duke-led research, published Nov. 28, 2012, in the Journal of the American Medical Association, suggests that doctors should more closely model the types of patients and the procedures followed in clinical trials when prescribing drugs in practice.
"Understanding whether real-world effectiveness matches the efficacy of clinical trials is important to assure that we are implementing and providing the best care possible," said lead author Adrian F. Hernandez, M.D., MHS, a cardiologist and member of the Duke Clinical Research Institute. "We are in an era where drugs can be efficacious, and the question is can they be effective and safe in clinical practice as they're being used. That's where we find differences and need more comparative effectiveness studies."
Key efficacy trials decades ago reported impressive benefits of aldosterone antagonist therapy, but doctors have long had questions about its safety for older and sicker patients who may be at risk for retaining high levels of potassium in their blood – a potentially fatal condition known as hyperkalemia.
Hernandez and colleagues used Medicare data to identify older patients who had been hospitalized for heart failure or weak pumping action called reduced ejection fraction. Among more than 5,880 eligible patients, 1,070 were discharged with prescriptions for aldosterone antagonist drugs, which inhibit sodium reabsorption in the kidneys to lower fluid retention and, as a result, improve heart function.
The research team found fewer benefits associated with the drugs than had originally been reported. There was no difference in deaths or hospital readmissions for cardiovascular events between the patients who went on the aldosterone antagonists and patients who did not. Patients taking the drugs were, however, less likely to be readmitted to the hospital for heart failure. At the same time, they were at significantly higher risk of readmission for hyperkalemia.
The study suggests that aldosterone antagonists might have limited success in reducing deaths among older patients. Potential reasons include a lack of adherence to therapy, and improper dosing and monitoring in practical use.
"Patient populations, monitoring, and procedures in clinical trials are different than in normal practice," Hernandez said. "High-risk patients, women and members of minority groups are typically underrepresented in clinical trials, while clinical trial participants tend to adhere to therapy and follow-up tests."
Hernandez said the study's findings highlight the importance of conducting clinical trials that can be easily generalized to real-world practice. At the same time, better protocols for aldosterone antagonist therapy could be established for doctors to ensure appropriate patient selection, correct dosing, medication adherence and early follow-up visits to screen for hyperkalemia.
"We can't have a paradigm where we give a pill and say come back in three months," Hernandez said. "Developing systems that encourage optimal use and monitoring of aldosterone antagonist therapy may help ensure that the effectiveness of this therapy in clinical practice approaches what was achieved in clinical trials."
###
In addition to Hernandez, study authors include Xiaojuan Mi, Bradley G. Hammill, Stephen C. Hammill, Paul A. Heidenreich, Frederick A. Masoudi, Laura G. Qualls, Eric D. Peterson, Gregg C. Fonarow, and Lesley H. Curtis.
The study was funded by the Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services, as part of the Developing Evidence to Inform Decisions about Effectiveness (DEcIDE) program. The American Heart Association also provided support.
END
CHICAGO – In an examination of cases of childhood pertussis in California, researchers found that children with pertussis had lower odds of having received all 5 doses of the diphtheria, tetanus, and acellular pertussis vaccine (DTaP) vaccine series; however the odds increased as the time since last DTaP dose lengthened, which is consistent with a progressive decrease in estimated vaccine effectiveness each year after the final dose of DTaP vaccine, according to a study in the November 28 issue of JAMA.
"Pertussis remains a poorly controlled vaccine-preventable disease ...
CHICAGO – Although current guidelines recommend 3 months of anticoagulation treatment after bioprosthetic aortic valve replacement surgery, a study that included more than 4,000 patients found that patients who had warfarin therapy continued between 3 and 6 months after surgery had a lower rate of cardiovascular death, according to a study in the November 28 issue of JAMA.
"Biological prostheses are preferred to mechanical valves for aortic valve replacement (AVR) surgery in elderly patients older than 65 years because of shorter life expectancy and lack of a need to ...
SALT LAKE CITY, Nov. 27, 2012 – A University of Utah study produced new mathematical support for a theory that explains why men in some cultures often feed and care for their sisters' children: where extramarital sex is common and accepted, a man's genes are more likely to be passed on by their sister's kids than by their wife's kids.
The theory previously was believed valid only if a man was likely to be the biological father of less than one in four of his wife's children – a number that anthropologists found improbably low.
But in the new study, University of ...
Coasts and estuaries are among the most rapidly developing areas on Earth. Night-time satellite images of the planet show that except Antarctica, continents are ringed with halos of brightly-lit human development. But coasts are also key wildlife sites. Every year, millions of waterbirds arrive from the Arctic to overwinter on UK coasts, yet scientists remain largely in the dark about how these birds respond to the bright lights of coastal cities and industry.
To shed light on the issue, Dr Ross Dwyer and colleagues from the University of Exeter investigated how artificial ...
Sea-levels are rising 60 per cent faster than the Intergovernmental Panel on Climate Change's (IPCC) central projections, new research suggests.
While temperature rises appear to be consistent with the projections made in the IPCC's fourth assessment report (AR4), satellite measurements show that sea-levels are actually rising at a rate of 3.2 mm a year compared to the best estimate of 2 mm a year in the report.
The researchers, from the Potsdam Institute for Climate Impact Research, Tempo Analytics and Laboratoire d'Etudes en Géophysique et Océanographie Spatiales, ...
ANN ARBOR, Mich. — About 70 percent of women who have both breasts removed following a breast cancer diagnosis do so despite a very low risk of facing cancer in the healthy breast, new research from the University of Michigan Comprehensive Cancer Center finds.
Recent studies have shown an increase in women with breast cancer choosing this more aggressive surgery, called contralateral prophylactic mastectomy, which raises the question of potential overtreatment among these patients.
The study found that 90 percent of women who had surgery to remove both breasts reported ...
Heart failure affects 3 per cent of the overall population, and exists in two forms: reduced ability to contract the heart and reduced ability to relax the heart. The former affects younger patients, mostly men, and is treatable. The latter, called HFPEF (heart failure with preserved ejection fraction), affects older patients and women, and until now there has not been any treatment available against the disease.
In the present study, a team comprising researchers at Karolinska Institutet, Linköping University, Stockholm South General Hospital and Karolinska University ...
Digoxin, a drug that has been used worldwide for centuries to treat heart disease, is associated with a significant increase in deaths in patients with atrial fibrillation (AF), according to results from a study published online today (Wednesday) in the European Heart Journal [1].
Digoxin is extracted from the foxglove plant (digitalis) and it helps the heart beat more strongly and with a more regular rhythm. It is commonly used in AF patients, and also in patients with heart failure. However, it can be problematic to use successfully as there is a narrow dose range at ...
People with an overactive thyroid gland (hyperthyroidism) carry a greater risk of developing irregular heart rhythm (known as atrial fibrillation) than those with normal thyroid function, finds a study published on bmj.com today.
As such, the researchers suggest there should be an increased focus on atrial fibrillation in patients with raised thyroid function.
Hyperthyroidism occurs when the thyroid gland makes too much thyroxine (thyroid hormone), causing many of the body's functions to speed up. About 1 in 100 women and 1 in 1,000 men develop hyperthyroidism at some ...
Women who develop pre-eclampsia during their first pregnancy (known as preterm pre-eclampsia) - and who don't go on to have any more children – are at greater risk of dying from heart disease in later life than women who have subsequent children, finds a study published on bmj.com today.
Women who develop the condition only in the final weeks of pregnancy (known as term pre-eclampsia) are at less risk.
This high risk to one child mothers has not been previously reported and suggests that these women need special monitoring, especially if their pre-eclampsia was preterm. ...
